sirolimus
sirolimus: 31 clinical trials tracked.
sirolimus evidence translation
What we can confirm
31 tracked trials
What it means
What to watch
Prepared research question
What is verified about sirolimus, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 1 study sponsors
Clinical Trial Registry Records (31)showing 10 most recent
Phase 4 Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Patients With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting (ENHANCE)
Primary endpoint: Cohort 1: Number of Participants with ALI
A Phase 2 Study of Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CONTRAC-2)
Primary endpoint: Overall response rate (ORR)
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
Primary endpoint: GVHD-free and rejection free survival (GRFS)
Open-Label, Cohort-Sequential Dose-Escalation and Dose-Confirmation Phase 1/2 Clinical Trial to Evaluate the Safety and Efficacy of Domatinostat in Combination With Sirolimus in Adolescents and Adults With Relapsed, Refractory Sarcoma and Osteosarcoma
Primary endpoint: Phase 1: Maximum Tolerated Dose (MTD)
A Phase IV Master Protocol of Cosibelimab in Special Populations With Advanced Cutaneous Squamous Cell Carcinoma (CosiMaster)
Primary endpoint: Best Overall Response Rate (BORR)
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial and Open-Label Extension Study of Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
Primary endpoint: Overall response rate (complete response + partial response) of ITP at Week 24
Characterization of mTOR Inhibitor Pharmacokinetics and Pharmacodynamics in Older Adults .
Primary endpoint: Cmax for Sirolimus
A Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ASP2957 in Male Participants With Invasive Ventilator-dependent X-linked Myotubular Myopathy
Primary endpoint: Number of participants with treatment emergent adverse events (TEAEs)
Ruxolitinib Based GVHD Prophylaxis Regimen for Older Adults Receiving Non-ATG Containing Non-Myeloablative Hematopoietic Cell Transplantation for Acquired Aplastic Anemia
Primary endpoint: Incidence of grades II-IV acute graft-versus-host disease (GVHD)
Part B- Phase I/II, Non-Randomized, Single Site Study, Open-label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Primary endpoint: Safety